CS MEDICA announces voluntarily extension of lock-up agreement for CEO and CFO
CS MEDICA A/S (“CS MEDICA” or the “Company”) announces today that CEO Lone Henriksen as well as CFO Gitte Lund Henriksen have extended their lock-up agreements for their shares in the Company until August 2023. In total, the lock-up agreements correspond to approximately 74 percent of the votes and capital in CS MEDICA.
CEO Lone Henriksen and CFO Gitte Lund Henriksen at CS MEDICA have extended their existing lock-ups for 12 months until end of August 2023. The original lock-up agreement was entered in connection with the listing on Spotlight Stock Market in August 2021. The lock-up prevents the selling of shares.
“We strongly believe in CS MEDICA’s bright future and by extending our lock-up agreement it reconfirms our commitments to the future development of the Company and we have no intention of selling our shares now,” says CEO Lone Henriksen.
For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
CS MEDICA A/S is a Danish medico cannabis company founded in 2011. CS MEDICA is committed to developing, manufacturing, and commercializing over-the-counter (OTC) medical device products containing cannabinoids. The Company runs its business through the two fully-owned subsidiaries, Galaxa Pharma A/S (distributor and representative of foreign manufacturers in the Nordic, registered medical device product distributor) and CanNordic A/S (Medical device developer and seller (BtB), registered medical device product manufacturer). CS MEDICA distributes products across the European borders and is headquartered in Copenhagen, Denmark.
The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information about CS MEDICA cs-medica.com.